BACKGROUND AND PURPOSE: Horseshoe kidney (HSK) is the most common renal fusion anomaly, with a prevalence of ∼1 in 400 and an incidence of urolithiasis between 20% and 60%. The role of shock wave lithotripsy (SWL) in patients with HSK remains poorly studied. METHODS: Data from all patients treated since January 1994 with a known HSK was reviewed. Analysis was restricted to all patients with a minimum follow-up of 2 weeks after SWL. Success was defined as patients who were stone-free or had asymptomatic, clinically insignificant residual fragments ≤ 4 mm. RESULTS: Data from 41 patients with HSK were analyzed (61 calculi). Mean stone size was 91.3 ± 71.6 mm(2); mean body mass index was 27.1 ± 5.3 kg/m(2). At 3 months, the single-treatment success and stone-free rates were 25.0% and 9.1%, respectively. The overall treatment success rate at 3 months was 63.6%, and the stone-free rate was 39.1%. Little incremental benefit was found for more than two SWL treatments per stone. The auxiliary treatment rate was 72.7%, with an efficiency quotient of 10.5%. On multivariate analysis, stone burden (p = 0.074), other calyceal location (p = 0.026), and body mass index (p = 0.013) were found to be prognostic for SWL success. CONCLUSIONS: Patients with HSK appear to have lower success and stone-free rates after SWL than patients with normal kidneys. This likely has to do with factors such as greater skin-to-stone distance (particularly for calyceal stones) and restricted urinary drainage. SWL may be offered to patients with a HSK once limitations in stone clearance have been considered.
BACKGROUND AND PURPOSE: Horseshoe kidney (HSK) is the most common renal fusion anomaly, with a prevalence of ∼1 in 400 and an incidence of urolithiasis between 20% and 60%. The role of shock wave lithotripsy (SWL) in patients with HSK remains poorly studied. METHODS: Data from all patients treated since January 1994 with a known HSK was reviewed. Analysis was restricted to all patients with a minimum follow-up of 2 weeks after SWL. Success was defined as patients who were stone-free or had asymptomatic, clinically insignificant residual fragments ≤ 4 mm. RESULTS: Data from 41 patients with HSK were analyzed (61 calculi). Mean stone size was 91.3 ± 71.6 mm(2); mean body mass index was 27.1 ± 5.3 kg/m(2). At 3 months, the single-treatment success and stone-free rates were 25.0% and 9.1%, respectively. The overall treatment success rate at 3 months was 63.6%, and the stone-free rate was 39.1%. Little incremental benefit was found for more than two SWL treatments per stone. The auxiliary treatment rate was 72.7%, with an efficiency quotient of 10.5%. On multivariate analysis, stone burden (p = 0.074), other calyceal location (p = 0.026), and body mass index (p = 0.013) were found to be prognostic for SWL success. CONCLUSIONS:Patients with HSK appear to have lower success and stone-free rates after SWL than patients with normal kidneys. This likely has to do with factors such as greater skin-to-stone distance (particularly for calyceal stones) and restricted urinary drainage. SWL may be offered to patients with a HSK once limitations in stone clearance have been considered.
Authors: Lisa Lavan; Thomas Herrmann; Christopher Netsch; Benedikt Becker; Bhaskar K Somani Journal: World J Urol Date: 2019-05-17 Impact factor: 4.226
Authors: Aditya S Pawar; Charat Thongprayoon; Wisit Cheungpasitporn; Ankit Sakhuja; Michael A Mao; Stephen B Erickson Journal: Urol Ann Date: 2018 Jan-Mar